Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges
Results from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (H...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2020-09-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2020-0021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572472580374528 |
|---|---|
| author | Lipska Katarzyna Gumieniczek Anna Filip Agata A. |
| author_facet | Lipska Katarzyna Gumieniczek Anna Filip Agata A. |
| author_sort | Lipska Katarzyna |
| collection | DOAJ |
| description | Results from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (HDAC) inhibitors (HDIs), being involved in the epigenetic regulation of gene expression. Afterward, VPA is shown to induce apoptosis and cell differentiation, as well as regulate Notch signaling. Moreover, it up-regulates the expression of certain G protein-coupled receptors (GPCRs), which are involved in various signaling pathways associated with cancer. As a consequence, some pre-clinical and clinical trials were carried out to estimate anticancer effectiveness of VPA, in monotherapy and in new drug combinations, while other SCFAs were tested in pre-clinical studies. The present manuscript summarizes the most important information from the literature about their potent anticancer activities to show some future perspectives related to epigenetic therapy. |
| format | Article |
| id | doaj-art-431f1114d646442a8cb40f7e01bd607a |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-431f1114d646442a8cb40f7e01bd607a2025-02-02T09:52:47ZengSciendoActa Pharmaceutica1846-95582020-09-0170329130110.2478/acph-2020-0021acph-2020-0021Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challengesLipska Katarzyna0Gumieniczek Anna1Filip Agata A.2Chair and Department of Medicinal Chemistry,Medical University of Lublin20-090Lublin, PolandChair and Department of Medicinal Chemistry,Medical University of Lublin20-090Lublin, PolandDepartment of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080LublinPolandResults from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (HDAC) inhibitors (HDIs), being involved in the epigenetic regulation of gene expression. Afterward, VPA is shown to induce apoptosis and cell differentiation, as well as regulate Notch signaling. Moreover, it up-regulates the expression of certain G protein-coupled receptors (GPCRs), which are involved in various signaling pathways associated with cancer. As a consequence, some pre-clinical and clinical trials were carried out to estimate anticancer effectiveness of VPA, in monotherapy and in new drug combinations, while other SCFAs were tested in pre-clinical studies. The present manuscript summarizes the most important information from the literature about their potent anticancer activities to show some future perspectives related to epigenetic therapy.https://doi.org/10.2478/acph-2020-0021valproic acidshort-chain fatty acidsanticancer activitieshistone deacetylase inhibitorspre-clinical and clinical studies |
| spellingShingle | Lipska Katarzyna Gumieniczek Anna Filip Agata A. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges Acta Pharmaceutica valproic acid short-chain fatty acids anticancer activities histone deacetylase inhibitors pre-clinical and clinical studies |
| title | Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges |
| title_full | Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges |
| title_fullStr | Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges |
| title_full_unstemmed | Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges |
| title_short | Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges |
| title_sort | anticonvulsant valproic acid and other short chain fatty acids as novel anticancer therapeutics possibilities and challenges |
| topic | valproic acid short-chain fatty acids anticancer activities histone deacetylase inhibitors pre-clinical and clinical studies |
| url | https://doi.org/10.2478/acph-2020-0021 |
| work_keys_str_mv | AT lipskakatarzyna anticonvulsantvalproicacidandothershortchainfattyacidsasnovelanticancertherapeuticspossibilitiesandchallenges AT gumieniczekanna anticonvulsantvalproicacidandothershortchainfattyacidsasnovelanticancertherapeuticspossibilitiesandchallenges AT filipagataa anticonvulsantvalproicacidandothershortchainfattyacidsasnovelanticancertherapeuticspossibilitiesandchallenges |